Ruthenium complexes bearing bis pyrazole (pzH) ligands, cis-[Ru (bpy) 2 (R-pzH) 2]
2+(bpy= 2, 2′-bipyridine, R=− H,− Cl), were examined as photoactivated anticancer …

Ruthenium (II) complexes containing diimine ligands have contributed to the development of
agents for photoactivated chemotherapy. Several approaches have been used to obtain …

Ruthenium drugs are potent anti-cancer agents, but inducing drug selectivity and enhancing
their modest activity remain challenging. Slow Ru ligand loss limits the formation of free sites …

Ruthenium complexes capable of light‐triggered cytotoxicity are appealing potential
prodrugs for photodynamic therapy (PDT) and photoactivated chemotherapy (PACT). Two …

The discovery of new light-triggered prodrugs based on ruthenium (II) complexes is a
promising approach for photoactivated chemotherapy (PACT). The light-mediated activation …

Metallo prodrugs that take advantage of the inherent acidity surrounding cancer cells have
yet to be developed. We report a new class of pH-activated metallo prodrugs (pHAMPs) that …

Rhenium (I) pyridocarbazole complexes with photoinduced antiproliferative activity are
reported. The substitutionally inert complexes induce cell death by singlet oxygen …

Photochemical ligand release from metal complexes may be exploited in the development of
novel photoactivated chemotherapy agents for the treatment of cancer and other diseases …

Ruthenium (II) polypyridyl complexes form a vast family of molecules characterized by their
finely tuned photochemical and photophysical properties. Their ability to undergo excited …

Ruthenium polypyridyl complexes may act as light-activatable anticancer prodrugs provided
that they are protected by well-coordinated ligands that i) prevent coordination of other …